India Globalization Capit... (IGC)
AMEX: IGC
· Real-Time Price · USD
0.31
0.01 (3.58%)
At close: May 19, 2025, 3:59 PM
0.29
-4.59%
After-hours: May 19, 2025, 06:24 PM EDT
3.58% (1D)
| Bid | 0.29 |
| Market Cap | 24.64M |
| Revenue (ttm) | 1.24M |
| Net Income (ttm) | -8.81M |
| EPS (ttm) | -0.12 |
| PE Ratio (ttm) | -2.58 |
| Forward PE | -2.92 |
| Analyst | Strong Buy |
| Ask | 0.33 |
| Volume | 170,273 |
| Avg. Volume (20D) | 290,242 |
| Open | 0.30 |
| Previous Close | 0.30 |
| Day's Range | 0.30 - 0.32 |
| 52-Week Range | 0.25 - 0.58 |
| Beta | 1.50 |
Analyst Forecast
According to 0 analyst ratings, the average rating for IGC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
India Globalization Capital Inc. is scheduled to release its earnings on Jun 23, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
+20.56%
Shares of cannabis stocks are trading higher follo...
Unlock content with
Pro Subscription
7 months ago
+1.17%
IGC Pharma shares are trading higher after a Form 4 filing showed that company director James P. Moran purchased 588,235 shares of common stock at $0.34 per share.
1 month ago · accessnewswire.com
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish HealthPOTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitati...
2 months ago · accessnewswire.com
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in FloridaPOTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's ...
